The Healthcare committee has had an eventful 2016. For those of you who have missed it, here is our recap of the year! To make sure that you don’t miss any of our committee events this year, join our mailing list to receive personal invites.


For more information on how you can be more involved with the committee, do feel free to drop me a note at


Healthcare 2016

photo_2016-08-01_18-07-19 photo_2016-08-01_18-07-40 photo_2016-08-01_18-07-44 photo_2016-08-01_18-07-50


On Thursday morning, the Healthcare Committee toured the facility of Yishun Community Hospital (YCH). YCH contains approximately 428-beds for patients and offers facilities to accomodate rehabilitative, dementia and palliative care treatment. Also, YCH is strategically located beside Khoo Teck Phuat Hospital to to allow both hospitals to coordinate their efforts to free up beds for acute patients. Patients who are not classified as requiring the intensive care services or facilities of an acute-care hospital may be hosted at the YCH. The objective of YCH would be to use therapeutic solutions to assist the recovery efforts of patients and allow them to function independently daily.


Dr. Benjamin SeetAudience

On April 28, Dr. Benjamin Seet, Executive Director of the Biomedical Research Council, Agency for Science, Technology and Research addressed the Healthcare Committee on what to expect in the coming 5 years. Tracing Singapore’s journey into the biomedical sciences, Dr Seet described the factors which led Singapore to diversify into this area and illustrated the emphasis of the recently announced RIE2020 tranche. Totaling SGD 19 billion, the RIE2020 plan will be focused on 4 domains; with a significant focus on translating research to healthcare outcomes.

Healthcare photo

August 2015:  The Future Growth of Singapore’s Biomedical Sciences Industry, Kevin Lai, Executive Director, EDB

August 2015:  Innovation for the Medical Industry, Gian Paolo Bassi, CEO, Dassault Systems

April 2015:  The Changing Landscape of Life Sciences and Industry Opportunities, Rakesh Sachdev, CEO Sigma-Aldrich

March 2015:  Collaborative Influence:  Industry Associations Driving Better Healthcare, Gary Prudent, Worldwide Chairman, Global Surgery Group, Johnson & Johnson

February 2015: A Paradigm Shift in Health Promotion: From Awareness to Behavior Change, Zee Yoong Kang, CEO, Health Promotion Board



The Healthcare committee kicked off the Tuesday morning by understanding the dynamics of medical education in Singapore. Dean, Duke-NUS Medical school Professor Thomas M. Coffman led the discussion. Dr. Thomas Coffman is James R. Clapp Professor of Medicine who spent almost 18 years as Chief of the Division of Nephrology and also served as Senior Vice-Chair in the Department of Medicine at Duke University Medical Center.

The Healthcare Committee members hosted John Lim, Executive Director for the Centre of Regulatory Excellence (CoRE), Duke-NUS Graduate Medical School Singapore (Duke-NUS) who shared the Centre’s work on the ever-important issue of Enhancing Biomedical Regulatory Expertise in Asia. The Centre aims to bridge regulatory gaps and promote regulatory excellence on a regional level to meet the needs of Asian populations. CoRE is supported by Singapore’s Ministry of Health (MOH), Health Sciences Authority (HSA) and the Economic Development Board (EDB.)

We will regularly update the blog after interesting meetings and share upcoming events and information related to healthcare. We hope the information benefits you and we welcome your feedback on the new look.


Stay tuned and look out for our next blog post!


Healthcare Committee

The Committee promotes and represents the healthcare industry in Singapore and the region by helping to shape healthcare policy, providing a channel for communication between members and government, and providing a platform for information sharing among various sectors, including service provision, pharmaceuticals, and medical device and equipment manufacturers.
Upcoming and Recent Committee Meetings


Christopher Hall

Christopher Hall

Johnson & Johnson

Hsien-Hsien Lei

Hsien-Hsien Lei


Jeff Weisel

Jeff Weisel

Ernst & Young

Join the Committee